Vertex Pharmaceuticals VRTX initiated the late-stage portion of the phase II/III AMPLITUDE study evaluating inaxaplin (VX-147) in APOL1-mediated kidney disease (AMKD), a genetic disorder affecting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback